Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.

Criteria

Main Inclusion Criteria:

• Men or women aged ≥ 19 years and ≤ 75 years

• Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization

• Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization

• Subjects who voluntarily signed a consent form

Main Exclusion Criteria:

• Ineligible for upper gastrointestinal endoscopy

• Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization

• Subjects with hypersensitivity to investigational drugs and similar drugs

• Pregnant or breastfeeding women